ArticleCellular & molecular biology letters2026
Targeting SLK protects against cerebral ischemia-reperfusion injury by regulating USP8-mediated HIF-1α stabilization and RhoA/ROCK activation.
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionAcute ischemic stroke (AIS) represents a major global contributor to mortality and chronic disability, with few effective therapeutic targets available. Identifying druggable genes associated with AIS is therefore critical for developing novel interventions.
methodsA comprehensive approach combining Mendelian randomization, multi-omics integration, and machine learning was employed to identify candidate druggable genes. Causal relationships were confirmed through genetic colocalization, and candidate genes were further validated in a retrospective clinical cohort comprising 60 patients who experienced AIS and 30 healthy controls. Functional and mechanistic investigations were performed using a male mouse middle cerebral artery occlusion/reperfusion (MCAO/R) model, oxygen-glucose deprivation/reperfusion (OGD/R) in HT22 cells, and 293 T cells.
resultsSLK emerged as a genetically causal AIS gene and a central component of the optimal predictive model. Plasma SLK levels were elevated in patients who experienced AIS, demonstrating strong diagnostic and prognostic value and serving as an independent predictor of unfavorable 3-month outcomes after adjusting for age, sex, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Knockdown of SLK conferred neuroprotection both in vivo and in vitro. SLK interacted with and phosphorylated the deubiquitinase USP8, increasing its activity and suppressing K48-linked polyubiquitination and degradation of HIF-1α. HIF-1α was stabilized following activation of the RhoA/ROCK signaling pathway, aggravating ischemic injury, whereas USP8 overexpression mitigated the neuroprotective effects of SLK knockdown.
conclusionsThese findings identify SLK as a neuron-specific proischemic factor and a potential therapeutic target, elucidate the SLK-USP8-HIF-1α-RhoA/ROCK pathway as a key mechanistic pathway, and highlight plasma SLK as a promising diagnostic and prognostic biomarker with translational relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.